Study Evaluating LXR-623 in Healthy Subjects

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00366522

Enrollment

Unknown

Registered

2006-08-21

Start date

2006-08-31

Completion date

2006-09-30

Last updated

2009-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Safety, Healthy, healthy subjects

Brief summary

To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.

Interventions

DRUGLXR-623

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

19 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

Inclusion: * Healthy, men or women, aged 19-50 years Exlcusion: * Use of any investigational or prescription drug within 30 days before study start * Any clinically imprtant medical disease or abnormal laboratory test results

Design outcomes

Primary

Measure	Time frame
Safety and Tolerability	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026